Physician profile
Joe Aoun
NPI 1023460276
$19,026.23
in general payments reported to CMS, 2019-2025
28 companies · $4,618 in 2025
The $4,618 reported for 2025 was more than what 82% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $743 · 2021: $857 · 2022: $3,110 · 2023: $4,849 · 2024: $4,424 · 2025: $4,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,804 · Travel and Lodging: $4,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,804.36 |
| Travel and Lodging | $4,087.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,382.73 | 2021-2025 | Corevalve Evolut R, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $6,238.83 | 2020-2025 | Mitraclip, Optis, Triclip |
| Boston Scientific Corporation | $1,225.64 | 2023-2025 | Avvigo Guidance System, Watchman Flx, Synergy |
| Abiomed | $1,021.01 | 2021-2025 | Impella |
| Edwards Lifesciences Corporation | $800.42 | 2023-2025 | Sapien 3 Ultra Resilia, Pascal |
| Philips North America LLC | $608.44 | 2023-2024 | (Bh4) Igt Devices Undivided, (Bq9) Coronary Ivus |
| Amgen INC. | $589.26 | 2019-2024 | Repatha |
| Biosense Webster, INC. | $547.19 | 2019-2025 | Nuvision Ice Catheter |
| Cardiva Medical, INC. | $306.64 | 2022 | |
| Pfizer INC. | $215.84 | 2019-2024 | |
| Astellas Pharma US INC | $159.83 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $147.70 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $134.94 | 2023-2025 | Lifevest |
| Heartflow, INC. | $113.08 | 2022 | |
| Penumbra, INC. | $88.36 | 2025 | Ruby Coil |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $78.48 | 2023 | Verquvo |
| Chiesi USA, INC. | $73.40 | 2019-2021 | |
| Getinge USA Sales, LLC | $65.57 | 2020 | |
| W. L. Gore & Associates, INC. | $55.09 | 2022-2025 | Gore Cardioform Septal Occluder |
| Lemaitre Vascular, INC. | $30.00 | 2025 | Artegraft Vascular Graft |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.55 | 2025 | Jardiance |
| Siemens Medical Solutions USA, INC. | $20.08 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.94 | 2020 | |
| Alnylam Pharmaceuticals INC. | $18.49 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.29 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $14.59 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $13.56 | 2022 | |
| Tactile Systems Technology INC | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Aoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.